Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis

Bruce E. Sands, Stefan Schreiber, Irina Blumenstein, Michael V. Chiorean, Ryan C. Ungaro, David T. Rubin

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

The emergence of advanced therapies [eg, biologics, Janus kinase inhibitors] over the past few decades has revolutionised the treatment of ulcerative colitis. However, the limitations of these therapies leave an unmet need for safer and more effective or convenient treatment options. There is growing interest in the development of novel oral small molecule therapies for the treatment of ulcerative colitis. Ozanimod is an oral small molecule therapy that is approved in the USA, the European Union, and other countries as the first sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active ulcerative colitis in adults. This review provides guidance for ozanimod use for the treatment of ulcerative colitis, based on the prescribing information, clinical trial and real-world data, and the authors' clinical experiences. This guidance outlines patient characteristics to consider when deciding if ozanimod treatment is suitable and describes how to educate patients on risks and best practices. It also details the nature and frequency of monitoring during treatment, which should be adapted to the individual patient based on pre-existing risk factors and events that possibly occur during treatment. This review also provides insights into the patient characteristics and clinical scenarios best suited for ozanimod treatment, based on its efficacy, safety profile, and risks compared with other therapies.

Original languageEnglish
Pages (from-to)2012-2025
Number of pages14
JournalJournal of Crohn's and Colitis
Volume17
Issue number12
DOIs
StatePublished - 1 Dec 2023

Keywords

  • S1P receptor modulator
  • Ulcerative colitis
  • ozanimod

Fingerprint

Dive into the research topics of 'Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis'. Together they form a unique fingerprint.

Cite this